SuperworthAssembly Biosciences market cap ASMB
Share price times shares outstanding: what the whole company sells for, since 2011.
- Today, Oct 23, 2026
- $404M
- Highest close in our data
- $1.2B
- Mar 2018
Assembly Biosciences is worth $404M at the close on Oct 23, 2026, at $19.84 a share.
That is up 80% over the last year and up 185% over five years.
Its highest close in our data was $1.2B in Mar 2018.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $404M | $363.9M | $745.2M | −24% |
| 2025 | $531.8M | $65.4M | $609M | +452% |
| 2024 | $96.4M | $53.1M | $123.3M | +79% |
| 2023 | $53.9M | $37.4M | $83.4M | −15% |
| 2022 | $63.4M | $54.6M | $110.2M | −43% |
| 2021 | $111.5M | $101.9M | $207.7M | −44% |
| 2020 | $199.8M | $160.8M | $801M | −63% |
| 2019 | $545.4M | $223.9M | $606.3M | −3% |
| 2018 | $563.2M | $493M | $1.2B | −28% |
| 2017 | $787.2M | $220.7M | $837.7M | +276% |
| 2016 | $209.3M | $84.1M | $243.7M | +62% |
| 2015 | $129.4M | $83.9M | $325.5M | +52% |
| 2014 | $85.1M | $21.1M | $90.9M | +19% |
| 2013 | $71.8M | $28.6M | $71.8M | +158% |
| 2012 | $27.8M | $27.8M | $153.1M | −72% |
| 2011 | $99.4M | $89.3M | $120.9M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Assembly Biosciences' size, closest first, today.
| Company | Market cap |
|---|---|
| ASMBAssembly Biosciences | $404M |
| ARVNArvinas | $477.3M |
| PBYIPuma Biotechnology | $568.9M |
| IRWDIronwood Pharmaceuticals | $571.7M |
| ZVRAZevra Therapeutics | $582.6M |
| CRMDCorMedix | $611.9M |
| COLLCollegium Pharmaceutical | $747.5M |
| NATRNatures Sunshine Products | $213.8M |
| ABUSArbutus Biopharma | $831M |
| AMPHAmphastar Pharmaceuticals | $1.1B |
| OMEROmeros | $1.2B |
| Peer median | $597.2M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Assembly Biosciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.